Reovirus works against prostate cancer tumours
Thursday, 11 March 2010- A virus that destroys cancer cells but leaves normal cells unharmed works against prostate cancer, according to a study conducted by Canadian researchers.
The virus also blasts lymphoid, colon, ovarian, breast, pancreatic, brain, lung, head and neck, and other cancer...
Edited by: JV
ASCO: PCA3 test assessed in two studies
Thursday, 11 March 2010- Researchers involved in the international Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial have reported that the urinary PCA3 test can predict biopsy outcome in men taking dutasteride. The details of two studies were presented at the 2010 American Society...
Edited by: ES
Specialist can influence treatment choice of elderly men with localised PCa
Wednesday, 10 March 2010- A new study published in the latest issue of the Archives of Internal Medicine by an investigator at The Cancer Institute of New Jersey (CINJ) and colleagues at Memorial Sloan-Kettering Cancer Center in New York, showed that the type of specialist consulted by elderly men...
Edited by: JV
Drinking alcohol raises PCa risk in African-Americans
Wednesday, 10 March 2010- Alcohol consumption may be associated with an increased risk of prostate cancer in African-American men, according to researchers.
A team led by Lionel L. Bañez, Assistant Professor of Medicine at Duke University Medical Center in Durham, N.C., prospectively collected...
Edited by: ES
Death after prostatectomy seldom due to prostate cancer
Tuesday, 9 March 2010- Cumulative mortality from prostate cancer 15 years after radical prostatectomy is six times lower than death from other causes, according to study findings presented at the Genitourinary Cancers Symposium. Among men older than 65 years at the time of surgery, cumulative...
Edited by: ES
New data supports new guidelines for the use of ERAs in dialysis patients
Tuesday, 9 March 2010- A new study helps dispel mounting confusion over the safety of blockbuster anaemia drugs — erythropoiesis-stimulating agents — for people with kidney disease requiring dialysis, as federal regulators prepare to decide whether to impose additional restrictions on their...
Edited by: ES
Cystoscopy is sufficient and cost-effective to detect bladder cancer recurrence
Monday, 8 March 2010- Researchers from the University of Texas M. D. Anderson Cancer Center, USA, found that cystoscopy, the standard for screening for recurrence of early-stage bladder cancer, is a cost-effective method of detecting tumours.
Adding other tests to cystoscopy increases the cost,...
Edited by: JV
PCA3 may pick up prostate cancers before biopsy in high-risk men
Monday, 8 March 2010- The Prostate Cancer Gene 3 (PCA3) test score at the time of a negative first biopsy predicted a positive rebiopsy two years later with 79.1% specificity and 36.4% sensitivity, according to retrospective analysis of a clinical trial to be reported at the Genitourinary Cancers...
Edited by: JV
Chemo drug cabazitaxel improves survival in refractory PCa
Friday, 5 March 2010- The novel chemotherapy drug cabazitaxel substantially improves survival in hormone- and chemotherapy-refractory prostate cancer, making it the first treatment of any kind to do so, according to the final results of a phase 3 study.
In a second-line treatment setting, the odds...
Edited by: JV
American Cancer Society supports informed decision-making for PCa screening
Friday, 5 March 2010- Principles of shared decision-making should guide a man's decision about screening for prostate cancer, according to updated guidelines from the American Cancer Society (ACS).
Beginning at age 50, asymptomatic average-risk men with at least a 10-year life expectancy should...
Edited by; JV
